Correction: Gastrointestinal stromal tumors with the use of ripretinib and sunitinib: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS). [PDF]
Che X, Zhu Y.
europepmc +1 more source
A retrospective pharmacovigilance study of ocrelizumab in multiple sclerosis: Analysis of the FDA Adverse Event Reporting System (FAERS) database. [PDF]
Ma HY, Ma YB, Ye PJ, Bai R.
europepmc +1 more source
What does data on adverse reactions reveal about benzodiazepines and suicide-related risk?: A disproportionality analysis using FDA FAERS pharmacovigilance data. [PDF]
Guo W, Zhang C, Yang R, Yan L.
europepmc +1 more source
Profiles and influencing factors of pulmonary fibrosis associated with biologic and conventional disease-modifying antirheumatic drugs for autoimmune diseases: a disproportionality study based on FAERS and VigiAccess. [PDF]
Zhang X +7 more
europepmc +1 more source
Drug-induced Sweet's syndrome: pharmacovigilance insights from FAERS with a cross-database consistency assessment in VigiBase via LASSO and multivariable logistic regression. [PDF]
Xie Y +5 more
europepmc +1 more source
Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors [PDF]
core +1 more source
Analyzing real-world adverse events of spironolactone with the FAERS database. [PDF]
Lin G, Chen R, Wen C, Li Z, Yan X, Li L.
europepmc +1 more source
FAER Supports Research to Advance Critical Care Medicine [PDF]
openaire +2 more sources
Response to FDA Adverse Event Reporting System (FAERS) Essentials: A Reflection on Study Conception. [PDF]
Reyes M, Potter E, Dal Pan G.
europepmc +1 more source
Cardioprotective Effects of PARP Inhibitors: A Re-Analysis of a Meta-Analysis and a Real-Word Data Analysis Using the FAERS Database [PDF]
Ja‐Young Han +4 more
openalex +1 more source

